Pseudovirus Service
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is threatening people's health around the world. The virus had already arrived in numerous areas of the world due to its potent transmissibility. As the virus continues its global spread, understanding of SARS-CoV-2 mechanism is critical for drug discovery and vaccine development. As a leading company, Creative Biogene provides reliable and high-quality pseudovirus service in support of SARS-CoV-2 studies. We will make our own contribution to fight against COVID-19 disease.

COVID-19 crises have led to enormous worldwide efforts to urgently develop drug treatments and vaccines effective against SARS-CoV-2. Due to the high infectivity and pathogenicity, SARS-CoV-2 should be dealt with in biosafety level 3 laboratories, which limit the anti-viral measure development. Pseudoviruses have the essential components for cell entry and viral infection, but lack of nucleic acid and lose self-replication ability. They have been regarded as the effective virological tools due to their safety and versatility, especially for appearing and re-appearing viruses. At present, researchers use pseudoviruses to mimic SARS-CoV-2 virus for further studies.
SARS-CoV-2 has four main structural proteins. The S protein is one of the key components to bind the receptor and mediate membrane fusion and virus entry. It is a main target for neutralizing antibodies and vaccine design. With extensive experience in pseudoviruses, Creative Biogene provides pseudovirus service based on lentiviral and VSV systems for SARS-CoV-2 studies. We have developed a pseudotype system with S protein of SARS-CoV-2 to support virus entry study in BSL2 facilities. Pseudovirus-based neutralization assays are provided for detecting neutralizing antibodies. In addition, multiple related pseudovirus products and custom services are also available.
The following is the details of pseudoviruses provided by Creative Biogene:
| Cat. No. | Product Name | Price |
| CoV-001 | SARS-CoV-2 S Pseudotyped GFP Lentivirus | Inquiry |
| CoV-001a | SARS-CoV-2 S Pseudotyped GFP Lentivirus (Alpha strain S) | Inquiry |
| CoV-001b | SARS-CoV-2 S Pseudotyped GFP Lentivirus (Beta strain S) | Inquiry |
| CoV-001d | SARS-CoV-2 S Pseudotyped GFP Lentivirus (Delta strain S) | Inquiry |
| CoV-001o | SARS-CoV-2 S Pseudotyped GFP Lentivirus (Omicron strain S) | Inquiry |
| CoV-002 | SARS-CoV-2 S Pseudotyped Luciferase Lentivirus | Inquiry |
| CoV-002a | SARS-CoV-2 S Pseudotyped Luciferase Lentivirus (Alpha strain S) | Inquiry |
| CoV-002b | SARS-CoV-2 S Pseudotyped Luciferase Lentivirus (Beta strain S) | Inquiry |
| CoV-002d | SARS-CoV-2 S Pseudotyped Luciferase Lentivirus (Delta strain S) | Inquiry |
| CoV-002o | SARS-CoV-2 S Pseudotyped Luciferase Lentivirus (Omicron strain S) | Inquiry |
| CoV-009 | SARS-CoV-2 S Pseudotyped mCherry Lentivirus | Inquiry |
| CoV-010 | SARS-CoV2 S-ΔG-mCherry Pseudotyped VSV | Inquiry |
| CoV-012 | SARS-CoV2 S-ΔG-GFP Pseudotyped VSV | Inquiry |
| CoV-013 | SARS-CoV2 S-ΔG-Luciferase Pseudotyped VSV | Inquiry |
| CoV-014 | SARS-CoV2 S-ΔG Pseudotyped VSV | Inquiry |
| CoV-015 | SARS-CoV-2 S Pseudotyped GFP-Luciferase Lentivirus | Inquiry |
| CoV-016 | SARS-CoV-2 S D614G Pseudotyped GFP-Luciferase Lentivirus | Inquiry |
| CoV-017 | SARS-CoV-2 S D614G Pseudotyped mCherry-Luciferase Lentivirus | Inquiry |
| CoV-018 | SARS-CoV-2 S E484K/N501Y Pseudotyped GFP Lentivirus | Inquiry |
| CoV-019 | SARS-CoV-2 S E484K/N501Y Pseudotyped Luciferase Lentivirus | Inquiry |
| CoV-020 | SARS-CoV-2 S N501Y Pseudotyped GFP Lentivirus | Inquiry |
| CoV-021 | SARS-CoV-2 S N501Y Pseudotyped GFP-Luciferase Lentivirus | Inquiry |
Why Choose Creative Biogene
- Mature and excellent platform
- Years of experience in pseudovirus
- Rapid turnaround time
- Competitive price
- Customized pseudovirus products and services
Together with global researchers and scientists, Creative Biogene is dedicating to provide pseudovirus service with high quality in support of SARS-CoV-2 research. More pseudoviruses are available at Creative Biogene. If you are interested in our pseudovirus service or have any additional requirements, please feel free to contact us.
In order to better support SARS-CoV-2 studies, related virus particles are provided in the table below:
| Cat.No. | Product Name |
|---|
| AD00537Z | Human ACE2 adenoviral particles |
| LV04219L | human ACE2 (NM_021804) lentivirus particles |
| AD16629Z | Human TMPRSS2 adenoviral particles |
| LV28259L | human TMPRSS2 (NM_005656) lentivirus particles |
| LV28260L | human TMPRSS2 (NM_001135099) lentivirus particles |
References:
- Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Fan, C., Huang, W., Xu, M., Wang, Y. (2020). Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerging Microbes & Infections, 9(1), 680–686.
- Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., Veesler, D. (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 181(2):281-292.e6.
- Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., Xiang, Z., Mu, Z., Chen, X., Chen, J., Hu, K., Jin, Q., Wang, J.,Qian, Z. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications, 11(1).
Publications
-
Li Z, Zhang X Q, Ho W, et al. Lipid‐Polymer Hybrid “Particle‐in‐Particle” Nanostructure Gene Delivery Platform Explored for Lyophilizable DNA and mRNA COVID‐19 Vaccines[J]. Advanced Functional Materials, 2022, 32(40): 2204462.
-
Almeida-da-Silva C L C, Matshik Dakafay H, Liu K, et al. Cigarette smoke stimulates SARS-CoV-2 internalization by activating AhR and increasing ACE2 expression in human gingival epithelial cells[J]. International journal of molecular sciences, 2021, 22(14): 7669.
-
Cutone A, Rosa L, Bonaccorsi di Patti M C, et al. Lactoferrin binding to SARS-CoV-2 spike glycoprotein blocks pseudoviral entry and relieves iron protein dysregulation in several in vitro models[J]. Pharmaceutics, 2022, 14(10): 2111.
* For research use only. Not intended for any clinical use.